

S1 Table. Complete list of adverse events and adverse drug reactions

System organ class Preferred term	Adverse events			Adverse drug reactions		
	No. (%)	No. of events	95% CI	No. (%)	No. of events	95% CI
Gastrointestinal disorders	61 (55.0)	111	45.22-64.41	56 (50.5)	101	40.80-60.08
Diarrhea	40 (36.0)	51	27.14-45.70	39 (35.1)	50	26.31-44.77
Stomatitis	19 (17.1)	19	10.63-25.43	19 (17.1)	19	10.63-25.43
Abdominal pain	8 (7.2)	8	3.16-13.71	6 (5.4)	6	2.01-11.39
Constipation	7 (6.3)	7	2.57-12.56	4 (3.6)	4	0.99-8.97
Nausea	7 (6.3)	7	2.57-12.56	7 (6.3)	7	2.57-12.56
Dyspepsia	5 (4.5)	6	1.48-10.20	4 (3.6)	4	0.99-8.97
Vomiting	5 (4.5)	5	1.48-10.20	4 (3.6)	4	0.99-8.97
Abdominal pain upper	2 (1.8)	2	0.22-6.36	2 (1.8)	2	0.22-6.36
Proctitis	2 (1.8)	2	0.22-6.36	2 (1.8)	2	0.22-6.36
Duodenal ulcer	1 (0.9)	1	0.02-4.92	-	-	-
Dysphagia ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Proctalgia ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Toothache ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
General disorders and administration site conditions	27 (24.3)	38	16.68-33.38	23 (20.7)	31	13.61-29.45
Asthenia	12 (10.8)	13	5.71-18.12	10 (9.0)	11	4.41-15.94
Fatigue	10 (9.0)	11	4.41-15.94	10 (9.0)	11	4.41-15.94
Mucosal inflammation	3 (2.7)	4	0.56-7.70	3 (2.7)	4	0.56-7.70
Generalized edema ^{a)}	2 (1.8)	2	0.22-6.36	-	-	-

Edema ^{a)}	2 (1.8)	2	0.22-6.36	1 (0.9)	1	0.02-4.92
Chest discomfort ^{a)}	1 (0.9)	2	0.02-4.92	1 (0.9)	2	0.02-4.92
Chest pain ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Death	1 (0.9)	1	0.02-4.92	-	-	-
Edema peripheral ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Pyrexia ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Skin and subcutaneous tissue disorders	26 (23.4)	32	15.91-32.41	24 (21.6)	30	14.37-30.44
Palmar-plantar erythrodysesthesia syndrome	13 (11.7)	16	6.39-19.19	13 (11.7)	16	6.39-19.19
Pruritus	3 (2.7)	3	0.56-7.70	3 (2.7)	3	0.56-7.70
Rash	3 (2.7)	3	0.56-7.70	3 (2.7)	3	0.56-7.70
Acne ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Alopecia	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Blister ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Decubitus ulcer ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Erythema	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Hand dermatitis ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Palmoplantar keratoderma ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Palmoplantar pustulosis ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Sebaceous hyperplasia ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Urticaria ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Vascular disorders	24 (21.6)	28	14.37-30.44	21 (18.9)	25	12.11-27.45
Hypertension	23 (20.7)	27	13.61-29.45	21 (18.9)	25	12.11-27.45
Deep vein thrombosis	1 (0.9)	1	0.02-4.92	-	-	-

Metabolism and nutrition disorders	21 (18.9)	26	12.11-27.45	18 (16.2)	21	9.90-24.41
Decreased appetite	15 (13.5)	15	7.77-21.31	15 (13.5)	15	7.77-21.31
Hyperkalemia	4 (3.6)	4	0.99-8.97	2 (1.8)	2	0.22-6.36
Dyslipidemia	2 (1.8)	2	0.22-6.36	1 (0.9)	1	0.02-4.92
Hypophagia	1 (0.9)	2	0.02-4.92	1 (0.9)	2	0.02-4.92
Gout ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Hyperglycemia	1 (0.9)	1	0.02-4.92	-	-	-
Hypoalbuminemia	1 (0.9)	1	0.02-4.92	-	-	-
Respiratory, thoracic and mediastinal disorders	18 (16.2)	21	9.90-24.41	10 (9.0)	12	4.41-15.94
Dysphonia	6 (5.4)	6	2.01-11.39	5 (4.5)	5	1.48-10.20
Cough	5 (4.5)	5	1.48-10.20	2 (1.8)	2	0.22-6.36
Dyspnea	2 (1.8)	2	0.22-6.36	1 (0.9)	1	0.02-4.92
Epistaxis	2 (1.8)	2	0.22-6.36	2 (1.8)	2	0.22-6.36
Chronic obstructive pulmonary disease ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Hemoptysis	1 (0.9)	1	0.02-4.92	-	-	-
Hiccups	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Oropharyngeal discomfort ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Pulmonary artery thrombosis	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Pulmonary embolism	1 (0.9)	1	0.02-4.92	-	-	-
Musculoskeletal and connective tissue disorders	11 (9.9)	12	5.05-17.04	6 (5.4)	7	2.01-11.39
Pain in extremity	3 (2.7)	3	0.56-7.70	3 (2.7)	3	0.56-7.70
Arthralgia	2 (1.8)	2	0.22-6.36	-	-	-
Flank pain	2 (1.8)	2	0.22-6.36	2 (1.8)	2	0.22-6.36

Back pain	1 (0.9)	1	0.02-4.92	-	-
Intervertebral disc disorder ^{a)}	1 (0.9)	1	0.02-4.92	-	-
Musculoskeletal chest pain	1 (0.9)	1	0.02-4.92	1 (0.9)	1 0.02-4.92
Myalgia	1 (0.9)	1	0.02-4.92	1 (0.9)	1 0.02-4.92
Pathological fracture ^{a)}	1 (0.9)	1	0.02-4.92	-	-
Nervous system disorders	11 (9.9)	12	5.05-17.04	7 (6.3)	7 2.57-12.56
Headache	4 (3.6)	4	0.99-8.97	3 (2.7)	3 0.56-7.70
Cerebral infarction	3 (2.7)	3	0.56-7.70	1 (0.9)	1 0.02-4.92
Diabetic neuropathy ^{a)}	1 (0.9)	1	0.02-4.92	-	-
Dizziness	1 (0.9)	1	0.02-4.92	1 (0.9)	1 0.02-4.92
Neuropathy peripheral ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1 0.02-4.92
Peripheral sensory neuropathy ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1 0.02-4.92
Tension headache	1 (0.9)	1	0.02-4.92	-	-
Endocrine disorders	10 (9.0)	10	4.41-15.94	8 (7.2)	8 3.16-13.71
Hypothyroidism	10 (9.0)	10	4.41-15.94	8 (7.2)	8 3.16-13.71
Infections and infestations	9 (8.1)	13	3.77-14.83	4 (3.6)	4 0.99-8.97
Urinary tract infection ^{a)}	3 (2.7)	4	0.56-7.70	-	-
Rhinitis ^{a)}	2 (1.8)	2	0.22-6.36	1 (0.9)	1 0.02-4.92
Cellulitis ^{a)}	1 (0.9)	1	0.02-4.92	-	-
Ecthyma ^{a)}	1 (0.9)	1	0.02-4.92	-	-
Endometritis ^{a)}	1 (0.9)	1	0.02-4.92	-	-
Gingivitis ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1 0.02-4.92
Herpes zoster ^{a)}	1 (0.9)	1	0.02-4.92	-	-

Oral candidiasis	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Pneumonia ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Renal and urinary disorders	9 (8.1)	10	3.77-14.83	5 (4.5)	6	1.48-10.20
Proteinuria	4 (3.6)	4	0.99-8.97	4 (3.6)	4	0.99-8.97
Dysuria ^{a)}	2 (1.8)	2	0.22-6.36	1 (0.9)	1	0.02-4.92
Chronic kidney disease ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Hematuria	1 (0.9)	1	0.02-4.92	-	-	-
Neurogenic bladder ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Nocturia ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Investigations	8 (7.2)	10	3.16-13.71	7 (6.3)	9	2.57-12.56
Alanine aminotransferase increased	2 (1.8)	2	0.22-6.36	2 (1.8)	2	0.22-6.36
Aspartate aminotransferase increased	2 (1.8)	2	0.22-6.36	2 (1.8)	2	0.22-6.36
Blood pressure increased	2 (1.8)	2	0.22-6.36	2 (1.8)	2	0.22-6.36
Liver function test increased	1 (0.9)	1	0.02-4.92	-	-	-
Thyroid function test abnormal	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Weight decreased	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
White blood cell count decreased	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Blood and lymphatic system disorders	3 (2.7)	3	0.56-7.70	2 (1.8)	2	0.22-6.36
Anemia	2 (1.8)	2	0.22-6.36	1 (0.9)	1	0.02-4.92
Thrombocytopenia	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Cardiac disorders	3 (2.7)	3	0.56-7.70	-	-	-
Angina unstable ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Palpitations ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-

Sinus bradycardia ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Hepatobiliary disorders	2 (1.8)	2	0.22-6.36	-	-	-
Cholecystitis acute	2 (1.8)	2	0.22-6.36	-	-	-
Psychiatric disorders	2 (1.8)	2	0.22-6.36	-	-	-
Depression ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Insomnia ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Reproductive system and breast disorders	2 (1.8)	2	0.22-6.36	1 (0.9)	1	0.02-4.92
Ejaculation failure ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Perineal pain ^{a)}	1 (0.9)	1	0.02-4.92	1 (0.9)	1	0.02-4.92
Ear and labyrinth disorders	1 (0.9)	1	0.02-4.92	-	-	-
Eustachian tube patulous ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Injury, poisoning and procedural complications	1 (0.9)	1	0.02-4.92	-	-	-
Pelvic fracture ^{a)}	1 (0.9)	1	0.02-4.92	-	-	-
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (0.9)	1	0.02-4.92	-	-	-
Malignant neoplasm progression	1 (0.9)	1	0.02-4.92	-	-	-
Total	92 (82.9)	338	74.57-89.37	79 (71.2)	264	61.80-79.37

CI, confidence interval. ^{a)}Adverse events were classified as unexpected adverse events.